Skip to main content

Advertisement

Log in

Adjuvant Bisphosphonates in Breast Cancer: The ABCSG-12 Study

  • CLINICAL TRIAL REPORT
  • Published:
Current Osteoporosis Reports Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Ovarian ablation in early breast cancer: overview of the randomized trials. Early Breast Cancer Trialists’ Collaborative Group [no authors listed]. Lancet 1996, 348:1189–1196.

  2. Hiraga T, Williams PJ, Ueda A, et al.: Zoledronic acid inhibits visceral metastases in the 4 T1/luc mouse breast cancer model. Clin Cancer Res 2004, 10:4559–4567.

    Article  CAS  PubMed  Google Scholar 

  3. Aft R, Watson M, Ylagan L, et al.: Effect of zoledronic acid on bone marrow micrometastases in women undergoing neoadjuvant chemotherapy for breast cancer [abstract 1021]. J Clin Oncol 2008, 26(15 Suppl):46S.

    Google Scholar 

  4. Diel IJ, Solomayer EF, Costa SD, et al.: Reduction in new metastases in breast cancer with adjuvant clodronate treatment. N Engl J Med 1998, 339:357–363.

    Article  CAS  PubMed  Google Scholar 

Download references

Disclosure

Dr. Larry J. Suva has given expert testimony on behalf of Novartis.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Larry J. Suva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Suva, L.J. Adjuvant Bisphosphonates in Breast Cancer: The ABCSG-12 Study. Curr Osteoporos Rep 8, 57–59 (2010). https://doi.org/10.1007/s11914-010-0012-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11914-010-0012-5

Keywords

Navigation